Cargando…
Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study
BACKGROUND: Currently, there is no approved treatment for the management of coronavirus disease (COVID-19). Drug repurposing of existing medications could be a possible way to find out a novel therapeutic entity to combat the COVID-19. AIM: To determine the clinical efficacy and safety of an Ayurved...
Autores principales: | Shukla, Umesh, Ujjaliya, Nitin, Gupta, Pankaj, Khare, Vivek, Yadav, Babita, Rai, Amit Kumar, Amin, Hetalben, Rana, Rakesh, Tripathi, Arunabh, Khanduri, Shruti, Sharma, Bhagwan Sahay, Chandrasekhararao, Bhogavalli, Srikanth, Narayanam, Dhiman, Kartar Singh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966758/ https://www.ncbi.nlm.nih.gov/pubmed/35370379 http://dx.doi.org/10.4103/ayu.ayu_11_21 |
Ejemplares similares
-
AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial
por: Reddy, R. Govind, et al.
Publicado: (2020) -
Disease Characteristics, Care-Seeking Behavior, and Outcomes Associated With the Use of AYUSH-64 in COVID-19 Patients in Home Isolation in India: A Community-Based Cross-Sectional Analysis
por: Srikanth, Narayanam, et al.
Publicado: (2022) -
Efficacy and safety of AYUSH-64 as standalone or adjunct to standard care in COVID-19: a structured summary of protocol for a systematic review
por: Rai, Amit Kumar, et al.
Publicado: (2022) -
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India
por: Singh, Harbans, et al.
Publicado: (2022) -
Dhatri Lauha in the management of iron deficiency anemia: A prospective open-label single-arm multi-center trial
por: Srikanth, Narayanam, et al.
Publicado: (2021)